MedTrace Logo

The CARDIO-TTRansform Scintigraphy Sub-study

NCT06073587 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-11-28

No results posted yet for this study

Summary

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

Conditions

  • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Interventions

DIAGNOSTIC_TEST

Scintigraphy scan

Scans will be performed as specified in the arm description.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-04
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06073587 on ClinicalTrials.gov